A new Chief Executive Officer to strengthen BioAlliance Pharma’s growth

BioAlliance Pharma SA (Euronext Paris –BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced the appointment of Judith Greciet as Chief Executive Officer, succeeding to Dominique Costantini, co-foundator and Chief Executive Officer, to be effective after the General Assembly Meeting of June 29, 2011.
Judith Greciet, PharmD, serves as Chief Operating Officer for BioAlliance Pharma from March 1st, 2011. Judith has a career in international pharmaceutical groups (notably Zeneca, Wyeth and Eisai) where she held increasing operational and strategic positions in the oncology and immunology areas, focusing on innovative products. Before joining BioAlliance, she managed Eisai France as President for 3 years.
« BioAlliance Pharma has developed a strong platform of expertise and know-how. The Company is now able to capitalize on this core to succeed in achieving its projects and accelerating its growth. I have chosen to pass on the torch to a manager able to succeed in this mission and I have total confidence in Judith to lead BioAlliance to the success”, commented Dominique Costantini.
“Enhanced by Dominique’s leadership, BioAlliance has achieved exceptional performances and has gained a unique leading position within the French Biotech area. It is now the time to start a second phase of its growth, with notably the development of its portfolios “Specialty products” and “Orphan oncology products, as well as to consider external growth opportunities”, declares Judith Greciet.
Besides, in agreement with the Board of Directors, Dominique Costantini has expressed wishes to put an end to her Board mandate as of December 31, 2011. She will specifically be in charge of developing partnerships and external growth projects.
As previously announced, the new executive/non executive team made of Judith Greciet, as Chief Executive Officer, and Patrick Langlois, expected to be co-opted as President of the Board, should take the lead of the Company after the General Assembly Meeting of June 29, 2011. Together with the Board members, they will commit to providing BioAlliance with a strong dynamics of growth to assure the success of the Company.